BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a ...

After a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech is sharing ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to ...

After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...

WASHINGTON, D.C.—FDA Commissioner Martin Makary, M.D., offered more details into the agency’s recently announced plans to ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

After publishing early clinical results of its ultrasound-activated brain tumor therapy this year, Alpheus Medical has raised ...

Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its ...